These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 15154700)

  • 1. Clinical implications of the differences between diagnostic 123I and post-therapy 131I scans.
    Cohen JB; Kalinyak JE; McDougall IR
    Nucl Med Commun; 2004 Feb; 25(2):129-34. PubMed ID: 15154700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Self-stunning in thyroid ablation: evidence from comparative studies of diagnostic 131I and 123I.
    Hilditch TE; Dempsey MF; Bolster AA; McMenemin RM; Reed NS
    Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):783-8. PubMed ID: 12029552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of 123I-diagnostic imaging in the follow-up of patients with differentiated thyroid carcinoma as compared to 131I-scanning: avoidance of negative therapeutic uptake due to stunning.
    Siddiqi A; Foley RR; Britton KE; Sibtain A; Plowman PN; Grossman AB; Monson JP; Besser GM
    Clin Endocrinol (Oxf); 2001 Oct; 55(4):515-21. PubMed ID: 11678835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 123I isotope as a diagnostic agent in the follow-up of patients with differentiated thyroid cancer: comparison with post 131I therapy whole body scanning.
    Alzahrani AS; Bakheet S; Al Mandil M; Al-Hajjaj A; Almahfouz A; Al Haj A
    J Clin Endocrinol Metab; 2001 Nov; 86(11):5294-300. PubMed ID: 11701695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Iodine-123 as a diagnostic imaging agent in differentiated thyroid carcinoma: a comparison with iodine-131 post-treatment scanning and serum thyroglobulin measurement.
    Urhan M; Dadparvar S; Mavi A; Houseni M; Chamroonrat W; Alavi A; Mandel SJ
    Eur J Nucl Med Mol Imaging; 2007 Jul; 34(7):1012-7. PubMed ID: 17256140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The management of differentiated thyroid cancer using 123I for imaging to assess the need for 131I therapy.
    Ali N; Sebastian C; Foley RR; Murray I; Canizales AL; Jenkins PJ; Drake WM; Plowman PN; Besser GM; Chew SL; Grossman AB; Monson JP; Britton KE
    Nucl Med Commun; 2006 Feb; 27(2):165-9. PubMed ID: 16404230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neck and whole-body scanning with 5-mCi dose of (123)I as diagnostic tracer in patients with well-differentiated thyroid cancer.
    Gulzar Z; Jana S; Young I; Bukberg P; Yen V; Naddaf S; Abdel-Dayem HM
    Endocr Pract; 2001; 7(4):244-9. PubMed ID: 11497474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of thyroid remnant/metastasis without stunning: an ongoing dilemma.
    Park HM; Park YH; Zhou XH
    Thyroid; 1997 Apr; 7(2):277-80. PubMed ID: 9133700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of a diagnostic dose of 185 MBq 131I on postsurgical thyroid remnants.
    Bajén MT; Mañé S; Muñoz A; García JR
    J Nucl Med; 2000 Dec; 41(12):2038-42. PubMed ID: 11138690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 74 MBq radioiodine 131I does not prevent uptake of therapeutic doses of 131I (i.e. it does not cause stunning) in differentiated thyroid cancer.
    McDougall IR
    Nucl Med Commun; 1997 Jun; 18(6):505-12. PubMed ID: 9259520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical effects of thyroid stunning after diagnostic whole-body scanning with 185 MBq 131I.
    Lees W; Mansberg R; Roberts J; Towson J; Chua E; Turtle J
    Eur J Nucl Med Mol Imaging; 2002 Nov; 29(11):1421-7. PubMed ID: 12397458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of diagnostic radioiodines on the uptake of ablative dose of iodine-131.
    Park HM; Perkins OW; Edmondson JW; Schnute RB; Manatunga A
    Thyroid; 1994; 4(1):49-54. PubMed ID: 8054861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sensitivity of 123I whole-body scan and thyroglobulin in the detection of metastases or recurrent differentiated thyroid cancer.
    de Geus-Oei LF; Oei HY; Hennemann G; Krenning EP
    Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):768-74. PubMed ID: 12029550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of diagnostic and therapeutic doses on thyroid remnant ablation rates.
    Karam M; Gianoukakis A; Feustel PJ; Cheema A; Postal ES; Cooper JA
    Nucl Med Commun; 2003 May; 24(5):489-95. PubMed ID: 12717064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreased uptake after fractionated ablative doses of iodine-131.
    Wu HS; Hseu HH; Lin WY; Wang SJ; Liu YC
    Eur J Nucl Med Mol Imaging; 2005 Feb; 32(2):167-73. PubMed ID: 15351912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are there disadvantages in administering 131I ablation therapy in patients with differentiated thyroid carcinoma without a preablative diagnostic 131I whole-body scan?
    Salvatori M; Perotti G; Rufini V; Maussier ML; Dottorini M
    Clin Endocrinol (Oxf); 2004 Dec; 61(6):704-10. PubMed ID: 15579184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 131I therapeutic efficacy is not influenced by stunning after diagnostic whole-body scanning.
    Dam HQ; Kim SM; Lin HC; Intenzo CM
    Radiology; 2004 Aug; 232(2):527-33. PubMed ID: 15286323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Absence of thyroid stunning after diagnostic whole-body scanning with 185 MBq 131I.
    Cholewinski SP; Yoo KS; Klieger PS; O'Mara RE
    J Nucl Med; 2000 Jul; 41(7):1198-202. PubMed ID: 10914909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic 123I and 131I activities and radioiodine therapy. Effects on urinary iodine excretion in patients with differentiated thyroid carcinoma.
    Meller B; von Hof K; Genina E; Deisting W; Meller J; Richter E; Baehre M
    Nuklearmedizin; 2005; 44(6):243-8. PubMed ID: 16400384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreased uptake of therapeutic doses of iodine-131 after 185-MBq iodine-131 diagnostic imaging for thyroid remnants in differentiated thyroid carcinoma.
    Leger FA; Izembart M; Dagousset F; Barritault L; Baillet G; Chevalier A; Clerc J
    Eur J Nucl Med; 1998 Mar; 25(3):242-6. PubMed ID: 9580856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.